Alume Biosciences
La Jolla, US · Founded 2017 · Delaware corporation · 1 known investors
Biotech@alumebioscience
Founders & leadership
QN
Quyen NguyenExecutive Officer, Director
KP
Kaveri ParkerExecutive Officer
BB
Brett BermanExecutive Officer, Director
JS
James SchmidtExecutive Officer
KK
Kim KamdarDirector
DB
Dan BradburyDirector
JM
Jean-Pierre MillonDirector
MM
Magda MarquetDirector
Investors · 1
Competitors · 6
by search overlapDiabetes Prevention Program20 shared keywords
ResearchGate13 shared keywords
Lumen11 shared keywordsLumen develops orally-delivered biologic drugs using genetically engineered spirulina algae, which expresses therapeutic proteins such as enzymes, antibodies, and cytokines that are spray-dried into shelf-stable powders and capsules. Its pipeline targets conditions including weight loss, C. difficile, Crohn's disease, ulcerative colitis, and respiratory infections.
Alumis9 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted oral therapies for immune-mediated diseases such as plaque psoriasis. Its precision drug-development approach is supported by a proprietary data analytics platform.
Startupintros9 shared keywordsStartup Intros is a platform for early-stage founders that handles Delaware C-Corp incorporation (EIN, founder stock, 83(b) filing), cap-table management with 409A, and investor matching through a double opt-in system. It also provides fundraising tools such as a data room with audit logs and round-tracking, positioning itself as an operating system for founders raising a round.
C&EN article8 shared keywords
Companies competing with Alume Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$2.2MraisedMay 2026 · 4 investors · BiotechnologyRule 506(b)
▶$2.2MraisedMay 2026 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kim KamdarDirector
- Jean-Pierre MillonDirector
- Kaveri ParkerExecutive Officer
- Brett BermanExecutive Officer, Director
- Dan BradburyDirector
- James SchmidtExecutive Officer
- Quyen NguyenExecutive Officer, Director
- Magda MarquetDirector
- Offering amount
- $8M
- Amount sold
- $2.2M
- Minimum investment
- $50K
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.9MraisedFeb 2026 · 92 investors · BiotechnologyRule 506(b)
▶$6.9MraisedFeb 2026 · 92 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kim KamdarDirector
- Kaveri ParkerExecutive Officer
- Jean-Pierre MillonDirector
- Brett BermanExecutive Officer, Director
- James SchmidtExecutive Officer
- Dan BradburyDirector
- Quyen NguyenExecutive Officer, Director
- Magda MarquetDirector
- Offering amount
- $23.5M
- Amount sold
- $6.9M
- Minimum investment
- $25K
- Sales commissions
- $662.8K
- Placement agents
- PHX Financial Inc.
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.8MraisedJan 2023 · 43 investors · BiotechnologyRule 506(b)
▶$12.8MraisedJan 2023 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kim KamdarDirector
- Jean-Pierre MillonDirector
- Magda MarquetDirector
- James SchmidtExecutive Officer
- Quyen T. NguyenExecutive Officer, Director
- Dan BradburyDirector
- Brett BermanExecutive Officer, Director
- Offering amount
- $45M
- Amount sold
- $12.8M
- Proceeds to insiders
- $153.6K
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedSep 2022 · 26 investors · BiotechnologyRule 506(b)
▶$4MraisedSep 2022 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Magda MarquetDirector
- Quyen T. NguyenExecutive Officer, Director
- Jean-Pierre MillonDirector
- Dan BradburyDirector
- Kim KamdarDirector
- James SchmidtExecutive Officer
- Brett BermanExecutive Officer, Director
- Offering amount
- $5.2M
- Amount sold
- $4M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedAug 2020 · 34 investors · BiotechnologyRule 506(b)
▶$4MraisedAug 2020 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kim KamdarDirector
- Magda MarquetDirector
- Brett BermanExecutive Officer, Director
- James SchmidtExecutive Officer
- Dan BradburyDirector
- Quyen T NguyenExecutive Officer, Director
- Jean-Pierre MillionDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$5.8MraisedJul 2019 · 40 investors · BiotechnologyRule 506(b)
▶$5.8MraisedJul 2019 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Quyen T NguyenExecutive Officer, Director
- James SchmidtExecutive Officer
- Brett BermanExecutive Officer
- Offering amount
- $8.6M
- Amount sold
- $5.8M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $937.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $3.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.